Skip to main content

Table 5 Follow-up midterm results

From: Should bioprostheses be considered the valve of choice for dialysis-dependent patients?

Complications

Group B(n = 36)

Group M(n = 33)

P Value

Valve-related

6(16.7%)

11(33.3%)

<0.05

 Bleeding event

0

2(6.1%)

<0.05

 Thromboembolism

0

3(9.1%)

<0.05

 PVE

2(5.6%)

2(6.1%)

NS

 Valve deterioration

0

0

NS

 perivalvular leak

1(2.8%)

1(3.0%)

NS

 Reoperation

3(8.3%)

3(9.1%)

NS

Cardiac death

2 (5.6%)

2(6.1%)

NS

 Heart failure

1(2.8%)

1(3.0%)

NS

 Arrhythmia

1(2.8%)

1(3.0%)

NS

Non-cardiac death

5(13.9%)

5(15.2%)

NS

 Malignancy

3(8.3%)

2(6.1%)

<0.05

 Other

2(5.6%)

3(9.1%)

<0.05

Late mortality

7(19.4%)

7(21.2%)

NS

  1. Group B, Biprosthesis valve; Group M, Mechanical valve; NS, not significant. PVE, prosthetic valve endocarditis.